Metaxalone submicron - Iroko Pharmaceuticals
Alternative Names: IC-1201; ICE-1201; Submicron metaxaloneLatest Information Update: 28 Apr 2025
At a glance
- Originator iCeutica
- Developer Iroko Pharmaceuticals
- Class Benzene derivatives; Ethers; Muscle relaxants; Oxazolidinones; Small molecules
- Mechanism of Action Central nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Musculoskeletal disorders
Most Recent Events
- 28 Apr 2025 Metaxalone submicron is still in phase I trials for Musculoskeletal disorders in USA (iCeutica pipeline, April 2025)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Musculoskeletal-disorders in USA (PO, Tablet)
- 29 Jun 2020 Metaxalone submicron is still in phase I development for Musculoskeletal disorders in USA (iCeutica pipeline, June 2020)